# US 2021/0061759 A1 · Crystal forms and production methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061759 A1
- Document ID: US20210061759A1
- Status: Published application
- Kind: A1
- Application number: 16/994,835
- Filed: 2020-08-17
- Published: 2021-03-04
- Earliest claimed: 2017-12-05
- Assignees: Sunovion Pharmaceuticals Inc.
- Applicants: Sunovion Pharmaceuticals Inc.
- Inventors: John R. Snoonian; Harold Scott Wilkinson; Haitao Zhang
- Web page: https://patentgrep.com/patent/US20210061759A1

## CPC

- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A crystalline form of (R)-(+)-amisulpride ethyl acetate solvate characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°.

### Claim 31 (depends on 30)

The crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, further characterized by the powder x-ray diffraction pattern further comprising peaks, in terms of 2-theta, at 14.1±0.2° and 25.3±0.2°.

### Claim 32 (depends on 30)

The crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, further characterized by the powder x-ray diffraction pattern further comprising a peak, in terms of 2-theta, at 14.1±0.2°.

### Claim 33 (depends on 30)

The crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, characterized by a powder x-ray diffraction pattern substantially in accord with FIG. 5.

### Claim 34 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 90% and a polymorph purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 80%.

### Claim 35 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, wherein the chemical purity of the composition is greater than about 95% (R)-(+)-amisulpride ethyl acetate solvate.

### Claim 36

A crystalline form of (S)-(−)-amisulpride ethyl acetate solvate characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°.

### Claim 37 (depends on 36)

The crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, further characterized by the powder x-ray diffraction pattern further comprising peaks, in terms of 2-theta, at 14.1±0.2° and 25.3±0.2°.

### Claim 38 (depends on 36)

The crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, further characterized by the powder x-ray diffraction pattern further comprising a peak, in terms of 2-theta, at 14.1±0.2°.

### Claim 39 (depends on 36)

The crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, characterized by a powder x-ray diffraction pattern substantially in accord with FIG. 8.

### Claim 40 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 90% and a polymorph purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 80%.

### Claim 41 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chemical purity of the composition is greater than about 95% (S)-(−)-amisulpride ethyl acetate solvate.

### Claim at position 14

42-44. (canceled)

### Claim 45

A method of making an enantiomerically pure ethyl acetate solvate crystalline form of amisulpride having a powder x-ray crystal pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°, the method comprising the steps of:
(a) providing a starting material comprising either R-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide or S-4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide;
(b) solvating the starting material with an ethyl acetate to form an ethyl acetate solvate with the starting material and first solvent; and
(c) isolating from the mixture of step (b) an ethyl acetate solvated crystalline form of the starting material having a powder x-ray crystal pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°.

### Claim 46 (depends on 45)

The method of claim 45, wherein the step of isolating comprises one or more of:
(a) adding an anti-solvent;
(b) cooling the mixture to −10±2° C.; and
(c) seeding the mixture.

### Claim at position 17

47-49. (canceled)

### Claim 50 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 90%.

### Claim 51 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 95%.

### Claim 52 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 99%.

### Claim 53 (depends on 30)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 30 wherein the chemical purity of the composition is greater than about 99% (R)-(+)-amisulpride ethyl acetate solvate.

### Claim 54 (depends on 34)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 34, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 95%.

### Claim 55 (depends on 34)

A composition comprising the crystalline (R)-(+)-amisulpride ethyl acetate solvate of claim 34, wherein the chiral purity of (R)-(+)-amisulpride ethyl acetate solvate is greater than about 99%.

### Claim 56 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 90%.

### Claim 57 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 95%.

### Claim 58 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 99%.

### Claim 59 (depends on 36)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 36, wherein the chemical purity of the composition is greater than about 95% (S)-(−)-amisulpride ethyl acetate solvate.

### Claim 60 (depends on 40)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 40, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 95%.

### Claim 61 (depends on 40)

A composition comprising the crystalline (S)-(−)-amisulpride ethyl acetate solvate of claim 40, wherein the chiral purity of (S)-(−)-amisulpride ethyl acetate solvate is greater than about 99%.

### Claim 62 (depends on 45)

The method of claim 45, wherein the ethyl acetate has a water content of less than about 3% by weight.

### Claim 63 (depends on 45)

The method of claim 45, wherein the step of solvating comprises basifying the ethyl acetate starting material mixture to raise the pH to greater than about 9.5.

### Claim 64 (depends on 45)

The method of claim 45, wherein after step (c) greater than 90% by weight of the starting material is in the crystalline form having a powder x-ray crystal pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°.

### Claim 65 (depends on 45)

The method of claim 45, wherein after step (c) greater than 95% by weight of the starting material is in the crystalline form having a powder x-ray crystal pattern comprising peaks, in terms of 2-theta, at 6.4±0.2°, 8.3±0.2°, and 20.8±0.2°.

### Claim 66 (depends on 46)

The method of claim 46, wherein the anti-solvent is methyl t-butyl ether.
